跳至主要内容
临床试验/ACTRN12605000170628
ACTRN12605000170628终止4 期

A placebo controlled study to test the effectiveness of atorvastatin and irbesartan on infarct size, cerebral perfusion, cerebral response to ischaemia and clinical outcome in acute ischaemic stroke

niversity of Western Australia0 个研究点目标入组 200 人开始时间: 2005年8月17日最近更新:
适应症

试验速览

阶段
4 期
状态
终止
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
ot stated 至 ot stated(—)
性别
All

入选标准

  • All patients admitted within 72 hours of onset of symptoms will be eligible for trial entry, unless exclusion criteria are met.If a person is unable to provide informed consent the next of kin will be sought to provide consent. Patients regaining capacity will be free to continue in or withdraw from the trial.

排除标准

  • Hypotension: Blood pressure less than 100mmHg systolic or 70mmHg diastolic. Hypertension (>220 mmHg) or clinical imperative to lower blood pressure. Hyperkalaemia: >5.5 mmol/L. Finger prick or laboratory blood sugar level > 13 mmol/L at baseline. Acute comorbid condition (such as myocardial ischaemia or sepsis). Active liver disease or unexplained elevation in transaminases. Already treated with ATRA, statin or more than one of an ACE inhibitor, non steroidal anti-inflammatory, potassium sparing diuretic, potassium salt or cyclosporin. Premenopausal female. Renal impairment (defined as creatinine >120 umol/L). History of sensitivity to statins, ATRA or contrast. Haemorrhage seen on initial CT.

研究者

发起方
niversity of Western Australia

相似试验

Acute Stroke Treatment with Atorvastatin and... | 临床试验